[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f2dt7rk373ojjv":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"medical_code":11,"short_description":12,"alternate_name":11,"disambiguating_description":11,"citations":13,"drugs":36,"specialties":42,"cover":11},921,"dt5dv96wzu4pli15mbtv5g37","multidrug-and-toxin-extrusion-transporter-1-inhibitors","Multidrug and Toxin Extrusion Transporter 1 Inhibitors",null,"MATE1 (SLC47A1) is a multidrug efflux pump that functions as a proton\u002Forganic cation antiporter and sits on the apical membrane, where it plays a physiological role in the excretion of cationic compounds - endogenous metabolites, drugs and toxins - through the kidney and liver, into urine and bile respectively. It is the exit step of a two-transporter route: the organic cation transporters OCT1 (SLC22A1) and OCT2 (SLC22A2) are both recorded on the basolateral membrane of hepatocytes and proximal tubules, taking cations up out of the blood, and MATE1 then pumps them out of the cell. Drugs in this class inhibit that exit step, so the substrate cation accumulates. FDA's drug-interaction table lists cimetidine and pyrimethamine as in vitro MATE1 inhibitors, and metformin, creatinine, MPP+ and tetraethylammonium as in vitro MATE1 substrates. The cited MED-RT class is not a useful membership list here: it holds only lofexidine.",[14,20,24,28,32],{"claims":15,"source":16,"licence":17,"source_url":18,"retrieved_at":19},"multidrug efflux pump functioning as a H(+)\u002Forganic cation antiporter; apical cell membrane; physiological role in the excretion of cationic compounds including endogenous metabolites, drugs and toxins through the kidney and liver, into urine and bile respectively","UniProt Multidrug and toxin extrusion protein 1 (Q96FL8)","not stated on source page","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FQ96FL8.json","2026-09-19",{"claims":21,"source":22,"licence":17,"source_url":23,"retrieved_at":19},"predominantly expressed at the basolateral membrane of hepatocytes and proximal tubules; uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow","UniProt Solute carrier family 22 member 1 (organic cation transporter 1) (O15245)","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FO15245.json",{"claims":25,"source":26,"licence":17,"source_url":27,"retrieved_at":19},"predominantly expressed at the basolateral membrane of hepatocytes and proximal tubules; basolateral cell membrane location; uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow","UniProt Solute carrier family 22 member 2 (organic cation transporter 2) (O15244)","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FO15244.json",{"claims":29,"source":30,"licence":17,"source_url":31,"retrieved_at":19},"in vitro inhibitors of MATE1 \u002F MATE-2K: cimetidine, pyrimethamine; in vitro substrates: creatinine, metformin, MPP+, tetraethylammonium","FDA, Drug Development and Drug Interactions Table of Substrates, Inhibitors and Inducers","https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers",{"claims":33,"source":34,"licence":17,"source_url":35,"retrieved_at":19},"the class holds only lofexidine and lofexidine hydrochloride","RxClass \u002F MED-RT class members, Multidrug and Toxin Extrusion Transporter 1 Inhibitors (N0000191423)","https:\u002F\u002Frxnav.nlm.nih.gov\u002FREST\u002Frxclass\u002FclassMembers.json?classId=N0000191423&relaSource=MEDRT",[37],{"id":38,"documentId":39,"slug":40,"name":41,"active_ingredient":41,"dosage_form":11,"administration_route":11},1581,"qbx84ldo1uoc46l9sj7m129b","ketoconazole","Ketoconazole",[]]